Correlation Between IL-10 and microRNA-187 Expression in Epileptic Rat Hippocampus and Patients with Temporal Lobe Epilepsy by Walid A. Alsharafi et al.
ORIGINAL RESEARCH
published: 02 December 2015
doi: 10.3389/fncel.2015.00466
Correlation Between IL-10 and
microRNA-187 Expression in
Epileptic Rat Hippocampus and
Patients with Temporal Lobe Epilepsy
Walid A. Alsharafi 1, Bo Xiao 1*, Mutasem M. Abuhamed 2, Fang-Fang Bi 1 and
Zhao-Hui Luo 1
1 Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China, 2 Department of Neurology,
Alkhadamat Altebia Hospital, Amman, Jordan
Edited by:
Antonio Gambardella,
University Magna Graecia Catanzaro,
Italy
Reviewed by:
De-Lai Qiu,
YanBian University, China
Yun-wu Zhang,
Xiamen University, China
*Correspondence:
Bo Xiao
xiaoboneuro@hotmail.com
Received: 12 August 2015
Accepted: 16 November 2015
Published: 02 December 2015
Citation:
Alsharafi WA, Xiao B,
Abuhamed MM, Bi F-F and Luo Z-H
(2015) Correlation Between IL-10
and microRNA-187 Expression in
Epileptic Rat Hippocampus and
Patients with Temporal Lobe Epilepsy.
Front. Cell. Neurosci. 9:466.
doi: 10.3389/fncel.2015.00466
Accumulating evidence is emerging that microRNAs (miRNAs) are key regulators in
controlling neuroinflammatory responses that are known to play a potential role in the
pathogenesis of temporal lobe epilepsy (TLE). The aim of the present study was to
investigate the dynamic expression pattern of interleukin (IL)-10 as an anti-inflammatory
cytokine and miR-187 as a post-transcriptional inflammation-related miRNA in the
hippocampus of a rat model of status epilepticus (SE) and patients with TLE. We
performed a real-time quantitative PCR and western blot on rat hippocampus 2 h,
7 days, 21 days and 60 days following pilocarpine-induced SE, and on hippocampus
obtained from TLE patients and normal controls. To detect the relationship between
IL-10 and miR-187 on neurons, lipopolysaccharide (LPS) and IL-10-stimulated neurons
were performed. Furthermore, we identified the effect of antagonizing miR-187 by its
antagomir on IL-10 secretion. Here, we reported that IL-10 secretion and miR-187
expression levels are inversely correlated after SE. In patients with TLE, the expression of
IL-10 was also significantly upregulated, whereas miR-187 expression was significantly
downregulated. Moreover, miR-187 expression was significantly reduced following IL-10
stimulation in an IL-10–dependent manner. On the other hand, antagonizing miR-187
promoted the production of IL-10 in hippocampal tissues of rat model of SE. Our findings
demonstrate a critical role of miR-187 in the physiological regulation of IL-10 anti-
inflammatory responses and elucidate the role of neuroinflammation in the pathogenesis
of TLE. Therefore, modulation of the IL-10 / miR-187 axis may be a new therapeutic
approach for TLE.
Keywords: temporal lobe epilepsy, interleukin-10, microRNA-187, anti-inflammation, cytokine
INTRODUCTION
Epilepsy is the most prevalent chronic neurological disorder that has been estimated to affect
0.8% of the world’s population. In clinical studies, temporal lobe epilepsy (TLE) is the most
common focal forms of drug-resistant epilepsy and characterized by recurrent unprovoked
seizures due to neuronal hyperactivity in the brain (Shorvon, 1996). However, biochemical
and molecular mechanisms of TLE are still incompletely understood. In the last two decades,
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extensive studies have provided evidence for the potential role
of neuroinflammation in the pathogenesis of human epilepsy
(Pitkänen and Sutula, 2002; Vezzani and Granata, 2005).
Interleukin (IL)-10 is a potent antiinflammatory cytokine that
has been found to deactivate dendritic cells and macrophages
after an inflammatory trigger, which inhibits the pro-
inflammatory cytokines production. Proinflammatory cytokines
are known to play a critical role in the pathogenesis of TLE
(Moore et al., 2001; Vezzani et al., 2002; Li et al., 2011). A
number of animal studies and clinical observations suggest
an anticonvulsant effect of IL-10 (Kurreeman et al., 2004;
Levin and Godukhin, 2007; Ishizaki et al., 2009; Youn et al.,
2012). A recent analysis indicated neuroprotective effects of
IL-10 against the development of hypoxia-evoked epileptiform
activity in rat hippocampal slices (Levin and Godukhin,
2007). In experimental hyperthermic seizures in rat models,
the seizure threshold temperature in IL-10 treated rats was
significantly upregulated compared to normal controls (Ishizaki
et al., 2009). Genetically, the frequencies of the IL-10 592C
allele and 1082A/-819C/-592C haplotype, that are reported
to be inducers of IL-10, were significantly downregulated in
patients with febrile seizures (FS) relative to normal controls,
suggesting that IL-10 is genetically associated with FS and
confers resistance to FS (Kurreeman et al., 2004; Ishizaki
et al., 2009). Furthermore, IL-10 has been found to provide
trophic and pro-survival cues to neurons during development
and was suggested that exogenously administration of IL-10
may have direct beneficial effects on neurons (Zhou et al.,
2009).
miRNAs are a class of short endogenous and small noncoding
RNAs, about 18–25 nucleotides in length, that function as key
regulators of gene expression at the post-transcriptional level
(Kim, 2005). miRNA is partially complementary to one or
more mRNA molecules to regulate gene expression of a wide
variety of genes involved in critical biological functions via
diverse manners such as mRNA cleavage, deadenylation and
translational repression. Novel miRNAs is created in non-coding
DNA sections from hairpins, duplication and modification of
already existed miRNAs or inverted duplications of protein-
coding sequences.
Evidence exists that miRNAs are important in the
pathogenesis of inflammatory and immune processes (O’Connell
et al., 2010). Recently, numerous studies have explored the
critical role of miRNAs in TLE using the pilocarpine animal
model and patients with TLE, and suggested new therapeutic
targets for the treatment of TLE (Kan et al., 2012b; Sano et al.,
2012; Alsharafi and Xiao, 2015; Alsharafi et al., 2015). Recent
studies have shown that miRNAs are involved in various vital
processes, including cell development, cardiac function, cell
differentiation, metabolism, apoptosis, cell proliferation, aging,
and organ development. Furthermore, miRNAs have been
implicated as regulators of about one-third of all protein-coding
genes.
miR-187 is a highly neuron-enriched miRNA which has
been intensively studied as a cancer-related miRNA and
considered as a promising biomarker for the early diagnosis
of a wide range of human cancers (He et al., 2012). Recently,
miR-187 has been implicated in the regulating of immune
and inflammatory processes (Guardia et al., 2013; Suojalehto
et al., 2014). Furthermore, miR-187 negatively regulates several
proinflammatory cytokines production produced by primary
human monocytes (Rossato et al., 2012). Other studies have
investigated the relationship between IL-10 andmiR-187 in other
systems, including monocytes and dendritic cells (Rossato et al.,
2012; Guardia et al., 2013).
The aim of the present study was to detect the dynamic
expression of IL-10 as anti-inflammatory cytokine and miR-187
as a post-transcriptional inflammation-related miRNA in the
hippocampus of rats following pilocarpine-induced status
epilepticus (SE) during the three phases of TLE development and
in patients with TLE.
MATERIALS AND METHODS
Animals
We started our experiment with fifty eight adult male Sprague–
Dawley (SD) rats (6–8 weeks of age, weighing 230–270 g)
obtained from the Animal Unit, Central South University,
China. Rats were randomly assigned to control C (n = 20) and
epileptic E (n = 38) groups. Animals were kept individually
in transparent Plexiglas cages (three animals per cage) on a
rotating 12-h light–dark cycle with an ambient temperature
of 20–25◦C and given ad libitum access to food and water.
All experimental procedures and animal care were carried
out according to protocols approved by the local authorities
for animal care, Xiangya Medical College, Central South
University.
Experimental Seizure Model
Thirty eight SD rats were injected with Lithium chloride (125
mg/kg, i.p., Sigma-Aldrich Chemie, Deisenhofen, Germany).
Eighteen hours after lithium chloride injections, rats were
injected with pilocarpine (20 mg/kg, i.p., Boehringer Mannheim,
USA) to induce a generalized SE, followed by a half dose
of pilocarpine (10 mg/kg, i.p.) every 30 min if a Racine
phase V, tonic clonic, seizure was not elicited (Racine,
1972). The maximum dose for pilocarpine injection was 60
mg/kg. Methylscopolamine (1 mg/kg, i.p.) was administered
15 min before pilocarpine treatment to reduce the peripheral
effects of the convulsions and thus enhance survival. SE
was terminated after 60 min with injections of chloral
hydrate (10%, 3 ml/kg, i.p.). All rats spent approximately
30 min of the 60 min SE phase in a Racine phase V
seizure and showed signs of a generalized SE. Following
pilocarpine administration, the rats were video-monitored
for 2 months (24 h/day), using an infrared ray monitor
during phases of early monitoring. Some animals exhibiting
seizures were confirmed using electroencephalogram (EEG)
recordings that displayed high frequency, high amplitude,
poly-spike paroxysmal discharges. Thirty two rats successfully
developed SE, four rats died after SE onset and two rats failed
to develop SE after repeated injections and were excluded
from the study. Saline control rats (n = 20) underwent
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identical treatment but received injections of comparable
volume of saline in lieu of pilocarpine and did not exhibit
any seizures. The behavior of rats was assessed by an
independent observer who was unaware of the treatments
given.
Based on epilepsy development phases, each group of rats
(experimental and control) were randomly divided into four
groups (n = 5 for each group): 2 h, 7, 21 and 60 days group. The
remaining experimental rats (n = 10) were used in the antagomir
experiments.
TLE Patients and Controls
Tissue samples were obtained at surgery from five patients
with unilateral drug refractory TLE and typical imaging
features and pathological confirmation of hippocampal sclerosis
(2 left and 3 right TLE), who had unilateral selective
amygdalohippocampectomy. Surgical samples were subjected
to routine histopathological examination. As control tissue,
five normal hippocampal samples were obtained from patients
with no history of any brain diseases. Neuropathologic studies
confirmed that the control tissues were normal. Clinical
information on patients with TLE and controls was mentioned in
our previous work (Table 1; Alsharafi and Xiao, 2015). This study
was approved by the Institutional Ethics Committee of Central
SouthUniversity and prior to analysis, written informed consents
were obtained from all patients.
Rat Tissue Preparation and RNA Isolation
Rats were decapitated at 2 h, 7, 21 and 60 days post-SE or saline
administration under deep anesthesia using 10% chloral hydrate
(5 ml/kg i.p.). After decapitation, hippocampus was quickly
removed from the brain, frozen on dry ice and stored at −80◦C
until use.
Total RNA isolation was carried out using Trizol method
(Invitrogen, Carlsbad, CA, USA) according to themanufacturer’s
protocol. RNA quality and quantity were determined at
260/280 nm using a NanoDrop ND-1000 spectrophotometer
(NanoDrop Technologies, Thermo Scientific, USA).
IL-10 Expression by qPCR in the
Hippocampi of Rats and TLE Patients
Total hippocampal RNA (1 µg) was reverse-transcribed using a
RevertAid First Strand complementary DNA (cDNA) Synthesis
Kit (Thermo Scientific’s Fermentas Molecular Biology Tools).
PCR was performed in a total volume of 20 µL using the
Platinum SYBR Green qPCR Super Mix UDG (Invitrogen, USA)
and ABI Mx3000P QPCR System (Stratagene) according to the
manufacturer’s instructions.
The relative expression level for IL-10 was calculated by
the comparative CT method. β-actin was used as an internal
control.
miR-187 Expression by qPCR in the
Hippocampi of Rats, and TLE Patients
cDNA synthesis was generated using the NCodeTM VILOTM
miR cDNA Synthesis Kit (Invitrogen, USA). qPCR reaction was
performed in a total volume of 20µL using the EXPRESS SYBRR
GreenERTM qPCR SuperMix Universal kit (Invitrogen, USA)
which contains EXPRESS SYBRr GreenERTM qPCR Supermix,
Universal qPCR Primer, and Rox Reference Dye according
to the manufacturer’s instructions. The expression of the U6
small nuclear RNA gene was used as an internal control. The
relative expression level for miR-187 was calculated using the
comparative CT method.
Western-Blot Analysis
The cytoplasmic extracts (30 µg total protein) were separated
by 12% sodium dodecyl sulfate–polyacrylamide (SDS-
polyacrylamide) gel and transferred onto a polyvinylidene
fluoride (PVDF) membrane using the Bio-Rad system (Bio-Rad,
USA) before blocking with TBST containing 5% nonfat-milk
for 2 h at room temperature with gentle shaking. Three washing
steps of 10 min each were performed after blocking and
incubation with the antibodies. The membrane was incubated
overnight at 4◦C with polyclonal antibodies against IL-10
(Abcam, Hong kong) at 1:500 dilutions and subsequently
incubated with a horseradish peroxidase conjugated sheep
TABLE 1 | Clinical information of patients with TLE and controls.
ID Sex Age (years) Duration of epilepsy (years) Side of Hippocampus side Antiepileptic drug (AED)
Epileptic 1 F 10 5 R PB, LAM, VPA
Epileptic 2 M 29 16 L VPA, CBZ, TOP
Epileptic 3 M 20 6 R CBZ, VPA, LAM
Epileptic 4 F 33 24 R VPA, CBZ, TOP
Epileptic 5 M 24 9 L CBZ, VPA, LEV
ID Sex Age (years) Post-mortem interval (hours) Side of Hippocampus side Causes of death
Control 1 M 65 14 L Pulmonary carcinoma
Control 2 F 23 19 R Acute pancreatitis
Control 3 M 19 16 R Cardiomyopathy
Control 4 M 52 22 L Respiratory failure
Control 5 F 27 16 L Hodgkin’s disease
CBZ, carbamazepine; PB, phenobarbitone; LAM, lamotrigine; LEV, levetiracetam; VPA, valproate acide; TOP, topiramate; R, right; L, left.
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anti-rabbit IgG (Amersham Biosciences, Piscataway, NJ, USA)
at 1:3000 dilutions at 37◦C for 1 h. β-actin expression was
used as an internal control. The reactions were detected using
enhanced chemiluminescence reagents (ECL; KPL, USA).
Integrated optical density (IOD) values of IL-10 protein and
β-actin were measured. The relative expression amount of
IL-10 protein was determined by the ratio of IL-10 protein/β-
actin.
Culture of Hippocampal Neurons
Primary hippocampal neurons were prepared from embryonic
day 18 (E18) rats as previously described (Brewer et al.,
1993). Rats were decapitated and their brains immediately
fetched and placed in phosphate buffered saline (PBS) at
4◦C. After removing blood vessels and pia mater, the
hippocampi were aseptically dissected. Tissues were minced,
washed, centrifuged, dissociated with dissociated with papain,
triturated, and plated on coverslips (25 mm) coated with
poly-L-lysine (Becton Dickinson) in in a medium consisting
of 85% high-glucose Dulbecco’s Minimum Essential Medium
(Invitrogen, USA), 15% fetal bovine serum (Invitrogen, USA),
and penicillin–streptomycin (106 U/l). Three hours later, the
plating medium was changed to feeding medium [neurobasal
medium (98%; Invitrogen, USA) supplemented with B27 (2%;
Invitrogen, USA), 2 mM glutamine, and penicillin–streptomycin
(106 U/l)] and cultured at 37◦C under 95% atmosphere and
5% CO2. Half of the feeding medium was changed with
fresh one every 3 days. All experiments were performed on
the 14th–15th day-in-vitro (DIV) to allow adequate neuronal
maturation.
Neurons were randomly divided into four groups: a control
group, a LPS-stimulated group, LPS + IL-10 stimulated group
and LPS + anti-IL-10 Ab group. In the control group,
neurons were cultured without serum Neurobasal-B-27 medium
for 30 h to explore the expression of miR-187 on the
resting neurons. While in the stimulated group, neurons
were cultured without serum Neurobasal-B-27 medium for
6 h and then with Neurobasal-B-27 medium and one or
more of the following reagents alone or in combination:
recombinant rat IL-10 200 U/mL (abnova), anti-rat IL-10
monoclonal antibody 1 µg/mL (Clone 2G101H7; Biocompare),
and LPS 100 ng/mL derived from Escherichia coli (Sigma) for
24 h to explore the effect of IL-10 stimulation on miR-187
expression.
miR-187 Antagomir Experiments
Briefly, miR-187 expression in rat hippocampus following
SE was antagonized using an antagomir that specifically
and efficiently targets miR-187. A miR-187 antagomir or an
antagomir-control (Ribo-Bio Co., Ltd., China) was dissolved
in an artificial CSF at a concentration of 20 nmol/mL
(1 nmol/50µl for each rat) and infused at a very slow rate
by micro-syringe into the lateral ventricle of the epileptic
rat (n = 10) as previously described (Löscher, 2002). The
experiment began at 60 min and ended at 4 h after SE onset.
At 7 days following SE onset, rats were decapitated under
deep anesthesia using chloral hydrate (10%, 5 ml/kg, i.p.)
and hippocampal tissue was quickly removed for detection of
miR-187 expression and detection of its critical downstream
molecules IL-10.
Statistics
All of the data are expressed as means ± standard deviation
(SD). Statistical significance was evaluated using Student’s t-test,
or one-way ANOVA performed using the SPSS 13.0 software.
The value of p < 0.05 was considered to be statistically
significant.
RESULTS
Behavior and Seizures in a Rat Model
In our experiment, pilocarpine was injected in a dose of
20 mg/kg, i.p. in pretreated rats with lithium chloride to
evoke SE in a rat model. SE was terminated by chloral
hydrate (3 ml/kg, i.p.) after 60 min. Following Lithium
chloride treatment, no behavioral changes were observed in
the treated animals, whereas significant behavioral changes
were markedly observed following a 5–35 min injection of
pilocarpine with akinesia, ataxic lurching, tremor, head bobbing,
masticatory automatisms with myoclonus of facial muscles,
and wet dog shakes at onset. In each pilocarpine-treated
animal, clinical signs of seizure activity were observed. All
rats exhibited a well-defined pattern of behavior following
pilocarpine injections. Behavioral changes were consistent with
the features of human TLE. Thirty two rats successfully
developed SE, four rats died after SE onset and two rats
failed to develop Racine stage IV-V of SE after repeated
injections and were excluded from the study. Saline control
rats (n = 20), which received injections of comparable
volume of saline in lieu of pilocarpine, did not exhibit
any seizures. Following pilocarpine administration, the rats
were video-monitored for 2 months (24 h/day), using an
infrared ray monitor during phases of early monitoring. Two
experimental rats were died between 24–72 h following SE as
a result of complications of seizures. The remaining animals
control group (n = 20) and experimental group (n = 30)
were kept individually in transparent Plexiglas cages (three
animals per cage) to be used for further experiments. The
acute seizure and acute control groups were sacrificed 2 h
after SE. The latent seizure and latent control groups were
sacrificed 7 days and 21 days post-SE without any behavioral
changes or seizures. Spontaneous seizures occurred mainly
60 days post-SE. Seizures were generally characterized by a
focal onset (immobility, mechanical mutation, mouth clonus,
forelimb clonus), occasionally culminating in a generalized
convulsive stage, lasting about 30 s to 1.5 min. Chronic
seizures occurred 60 days post-SE. At this time point, all
of the remaining pilocarpine-induced rats manifested with
chronic TLE, experiencing seizures one to several times
per day with symptoms as described above. Some animals
exhibiting seizures were confirmed using EEG recordings that
displayed high frequency, high amplitude, poly-spike paroxysmal
discharges.
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Dynamic Expression Pattern of IL-10 in
Rats During the Three Phases of TLE
Development
qPCR results showed significant upregulation of IL-10 gene
expression in the rat hippocampal tissues during the latent
and chronic phases of TLE development (∗p < 0.05) with
higher expression at 21 days compared to 7 days and showed
its highest expression in the chronic phase (60 days post-
SE). In the acute phase (2 h post-SE), IL-10 expression
levels were no different between the epileptic and control
groups. In rat hippocampal tissues, IL-10 expression was
normalized to that of β-actin (Figure 1A). Our results were
confirmed by detecting IL-10 protein expression by western
blot, which showed similar dynamic changes as gene expression
(Figure 1B).
Relative Expressions of IL-10 in Patients
with TLE
qPCR results showed also significantly upregulation of IL-
10 gene expression in the hippocampal tissues obtained
from patients with TLE compared to tissues from normal
controls (∗p < 0.05). We confirmed our results by
detecting the expression of IL-10 protein by western
blot, which also showed upregulation in the patients’
tissues compared to normal controls. In the patients’
tissues, IL-10 expression was normalized to that of β-actin
(Figures 1C,D).
FIGURE 1 | (A) Interleukin (IL)-10 dynamic expression patterns in the latent
and chronic phases of TLE development in a rat model. qPCR results showed
significant upregulation occurred in these two phases of TLE, with higher
expression in the chronic phase. (B) IL-10 protein expression by western blot
in the three phases of TLE development in a rat model also showed similar
dynamic changes as gene expression. (C) IL-10 expression in hippocampal
tissues obtained from patients with TLE and normal controls. qPCR results
showed significant upregulation occurred in the TLE patients compared to
normal controls. (D) IL-10 protein expression by western blot also showed
upregulation in the patients’ tissues compared to normal controls. (Data are
presented as the mean ± sprague–dawley (SD), ∗p < 0.05; n = 5/group).
HC, human control; HE, human epileptic.
miR-187 Expression in Rats During the
Three Phases of TLE Development
qPCR results showed significant downregulation of miR-
187 expression in the rat hippocampal tissues in the latent
and chronic phases of TLE development (∗p < 0.05).
Expression was lower in the 21 days group compared to
the 7 days group and showed its lowest expression in the
chronic phase (60 days post-SE). Notably, no significant
deregulation was detected in the acute phase (2 h post-
SE). In rat tissues, miR-187 expression was normalized
to that of the U6B small nuclear RNA gene (rnu6b;
Figure 2A).
miR-187 Expression in Patients with TLE
qPCR results showed also significant downregulation of miR-187
expression in the hippocampal tissue of TLE patients relative to
controls (∗p < 0.05). In the tissues obtained from patients, miR-
187 expression was normalized to rnu6b (Figure 2B).
Effect of Modulation of IL-10 on miR-187
Expression in the Neurons
qPCR results revealed a significant downregulation in miR-
187 expression in the neurons after stimulation with LPS than
controls (∗p < 0.05). Furthermore, simultaneous addition of
IL-10 to LPS-stimulated neurons suppressed the expression of
miR-187 compared to LPS-stimulated neuron group, whereas
simultaneous addition of anti-IL-10 Ab to LPS-stimulated
neurons restored the expression of miR-187 (Figure 3). These
data point to miR-187 as a LPS-related miRNA up regulated
by IL-10. miR-187 expression was normalized to that of the
rnu6b.
Effect of miR-187 Antagomir in IL-10
Expression Level
qPCR results showed that IL-10 expression level is increased
at 7 days post-SE in the rat hippocampal tissues both before
FIGURE 2 | (A) miR-187 relative dynamic expression in the three phases of
TLE development in a rat model. qPCR results showed significant
downregulation occurred in the latent and chronic phases compared to
controls, with lowest expression in the chronic phase. In the acute phase, no
significant deregulation was observed. (B) Relative expression of miR-187 in
the hippocampal tissues obtained from patients with TLE and normal controls.
qPCR results showed significant downregulation occurred in the TLE patients
compared to normal controls (n = 5/group; ∗p < 0.05). HC, human control;
HE, human epilepsy.
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FIGURE 3 | qPCR results showed a significant downregulation of
miR-187 in the neurons after treatment with LPS than control neurons.
A dramatically downregulation of miR-187 in the neurons was detected after
treatment with LPS + IL-10 than control neurons, while simultaneous addition
of anti-IL-10 Ab to LPS-stimulated neurons restored the expression of
miR-187 (Data are presented as the mean ± SD, ∗p < 0.05; n = 5/group).
LPS, lipopolysaccharides; Ab, antibody.
and after miR-187 antagomir/antagomir-control treatments.
Stimulation of IL-10 expression level was markedly observed in
the miR-187 antagomir group compared to the antagomir-
control-treated group (Figure 4A). We confirmed our
results by western blot that also detected an upregulation
in the expression of IL-10 protein at 7 days post-SE in
the rat hippocampus when compared with control. The
expression of IL-10 protein at 7 days post-SE in the rat
hippocampus increased in the miR-187 antagomir-treated group
when compared with the antagomir-control-treated group
(Figure 4B).
DISCUSSION
Despite the available extensive literature of studies on epilepsy,
no treatments to avoid or reverse the development of epilepsy
have been developed. Currently available antiepileptic treatments
are not effective in 1/3 of patients. Recently, lines of research
are beginning to investigate the role of inflammation and
cytokine release in seizures and epileptogenesis in experimental
models and human TLE (Vezzani et al., 2002; Dubé et al.,
2010; Youn et al., 2012). Auvin et al. (2010) found that
inflammation worsens the consequences of epilepsy in the
animal models. Since IL-10 plays a critical role in immune
and inflammatory responses and a defect in its production
has been attributed to certain inflammatory diseases. Better
understanding of which molecules and functional mechanisms
those regulate the expression of this anti-inflammatory cytokine
may offer new therapeutic targets for the treatment of TLE.
In recent years, altered miRNA expression in brain has
been extensively studied for its critical function related to
a wide range of neurological diseases including epilepsy.
Several target studies, as well few genome-wide miRNA
expression profiling studies, have reported abnormal miRNA
expression in tissue with mesial temporal sclerosis, both in
patients and in animal models. Interestingly, these studies
FIGURE 4 | The results of the miR-187 antagomir experiment. (A) qPCR
results showed significant upregulation of IL-10 expression at 7 days
post-status epilepticus (SE) in the rat hippocampal both before and after
miR-187 antagomir/antagomir-control treatments. (B) Detection of IL-10
protein expression by western blot showed similar dynamic changes as gene
expression (∗p < 0.05, ∗∗p < 0.01, n = 5/group).
revealed a tight correlation between miRNA deregulations
and neuroinflammation, seizure-induced neuronal death
and other related biological pathways. In our previous
studies we demonstrated the expression profile of miRNAs
in the hippocampus in a rat model of TLE and showed
the neuroprotective effect of targeting miR-34a (Hu et al.,
2011, 2012). Importantly, inflammation, stress signaling
and neuronal excitation are among the pathways most
impacted. Overall, it is now clear that miRNAs regulate a
wide variety of pathogenic and functional mechanisms during
TLE development.
In the present study, we first demonstrated an association
between IL-10 as an anti-inflammatory cytokine and miR-
187 as a post-transcriptional inflammation- related miRNA
during the three phases of TLE development in a rat
model, and we confirmed our results by detecting their
expressions in patients with TLE, which are equal to the
chronic phase in the rat model. In addition, we examined
the effect of modulation of IL-10 expressions on miR-187
expressions in vitro on the neuron level and the effect of
antagonizing miR-187 on the expression of IL-10 to identify
the correlation between miR-187 and IL-10 expression levels.
We observed that IL-10 secretion and miR-187 expression
levels are inversely correlated after SE, in which IL-10
expression was highest in the chronic phase, when expression
of miR-187 was at its lowest level; miR-187 expression
was highest in the latent phase, when IL-10 expression
was at its lowest level. In the acute phase no significant
deregulation was detected in both IL-10 and miR-187. This
suggests their underlying functions in the process of TLE
development.
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In the acute phase, IL-10 expression started to be detectable
after 2 h, however, no statistical significance was found. In
association with our observation, Youn et al. (2012) also found
that IL-10 expression takes from 2–3 days to be significantly
detectable in plasma in neonatal seizures induced by hypoxic-
ischemic encephalopathy.
In the latent phase, IL-10 showed a significant upregulation
with a higher expression at 21 days post-SE compared with 7 days
group. The rapid and prominent expression of IL-10 in the latent
phase may also corresponds to the changes in gene expression
involved in inflammatory response occur during latent phase
(Aronica et al., 2000, 2001; Gorter et al., 2006).
In the chronic phase, IL-10 showed its highest expression.
These results corroborate other findings that showed an
increased in the IL-10 production of chronic epileptic rats
(Costa-Ferro et al., 2011; Ferrazoli et al., 2013). Consistent
with the chronic phase findings in rat, we revealed an
upregulation of IL-10 in patients with TLE, which has
previously been shown in TLE patients (Kan et al., 2012a).
This upregulation of IL-10 expression was associated with the
onset of chronic spontaneous seizures. Our results support the
role of chronic inflammation as an insistent guest in the brain
undergoing epileptogenesis, being manifested by activations
of multiple inflammatory markers including cytokines. On
the other hand, our findings support the idea that IL-10
promotes an anti-inflammatory action, mediating inflammatory
cascades triggered by induced SE. Therefore, upregulation
of IL-10 during epileptogenesis and chronic phase of TLE
development could be crucial for arresting the development
of TLE.
Interestingly, miR-187 exhibited an opposite expression
manner to IL-10 which was significantly downregulated during
the latent and chronic phases of TLE development in a gradual
manner. In the acute phase, miR-187 expression was almost
equal to expression values in the control group. Notably, several
profiling studies have shown that miR-187 is not deregulated in
the acute phase of TLE (Hu et al., 2011, 2012), which coincides
with our findings in this study.
The latent phase statistically reduced the expression of
miR-187 compared to normal controls and its expression
being more decreased in 21 days than in 7 days group.
This may relate to the change in IL-10 expression which
exhibits an opposite dynamic pattern. The same expression
was also found at 7 days post-SE by Bot et al. (2013).
In their study, they also evaluated the prolonged expression
of miR-187 in tissues collected from different time points
(7–90 days post-SE) which was also downregulated. This
significant decrease in miR-187 expression which is associated
with the significant increased level of IL-10 expression in
this animal model support the hypothesis that miR-187 may
represent an attempt to regulate the anti-inflammatory response
of IL-10 by inducing its expression level (Rossato et al.,
2012).
In the chronic phase, miR-187 expression reached its lowest,
which was confirmed by its downregulation in patients with
TLE. In association with our observation, several profiling
studies have shown that miR-187 is downregulated in
the chronic phase of TLE either in experimental models
or patients with TLE. Kretschmann et al. (2015) found a
significant downregulation of miR-187 expression at 28
days pilocarpine-induced SE in mice. Bot et al. (2013)
also reported a downregulation in this miRNA at 30
days after SE induced by amagdala electrical stimulation.
Another study by Gorter et al. (2014) also detected a
significant decreased of miR-187 at 3–4 months following
SE induced by electrical stimulation of angular bundle in
rats. McKiernan et al. (2012) found that mature miR-187
was decreased in association with dicer loss in patients
with TLE and HS. This suggests that miR-187 may play
a special role in the pathogenesis of TLE. Several studies
have suggested a link between miR-187 and chronic human
inflammatory diseases (Holliday et al., 2011; Guardia et al.,
2013; Suojalehto et al., 2014). In previous animal studies and
clinical observations, inflammation-related miRNAs were also
detected deregulated during the chronic phase of TLE (Omran
et al., 2012; Ashhab et al., 2013). Therefore, the dramatic
downregulation of miR-187 expressions in both rat models and
patients with TLE during epileptogenesis and chronic phase
indicates their underlying functions in the process of TLE
development.
Recently, many reports have provided insights into the
involvement of miRNAs in the posttranscriptional regulation
of cytokine genes and vise versa (Liu et al., 2011; Omran
et al., 2012; Ashhab et al., 2013).To investigate the relationship
between IL-10 and miR-187, we evaluated their relationship on
neurons. Furthermore, we explored the effect of antagonizing
of miR-187 in IL-10 expression levels. IL-10 alone has been
shown to be a relatively weak stimulus, but it strongly
synergized with LPS in alteration of miR-187 expression
(Rossato et al., 2012). Several lines of evidence clearly point
to the requirement for IL-10 in the reduction of miR-
187 expression in LPS-activated neurons. Stimulation of the
neurons with LPS leads to a significant downregulation of
miR-187 expression compared to the resting state. miR-187
expression failed to be downregulated when IL-10 is blocked
with anti–IL-10 antibody. Furthermore, IL-10 directly abolished
LPS-reduced miR-187 transcription, which is potentiated
in the presence of IL-10–blocking antibodies. Therefore,
downregulation of miR-187 in response to LPS may be required
for proper IL-10 production during TLE. On the other hand,
antagonizing of miR-187 function by antagomir in the post-
SE rat hippocampus significantly increased the expression levels
of IL-10 after antagonizing miR-187. Thus, miR-187 mediated
posttranscriptional control could be involved in fine tuning
the requirement level of IL-10 expression in anti-inflammatory
responses following SE.
Overall, our observations represent evidence that miR-187 are
strongly involved in the anti-inflammatory functions of IL-10
during TLE. These results are supported by findings that suggest
a major role for miR-187 in the physiological regulation of
IL-10–driven anti-inflammatory responses by inhibiting several
proinflammatory cytokins production including TNF-α, IL-6
and IL-12p40 (Rossato et al., 2012). However, further studies are
needed to evaluate the exact underlying mechanisms.
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CONCLUSION
The current study shows that IL-10 and miR-187 are mediated
in the pathogenesis of TLE development and their opposite
expression patterns in the phases of TLE development may
suggest an interactive relationship between the two markers,
suggesting that miR-187 may play a critical role in the
modulation of the neuroinflammatory response during the
pathogenesis of TLE. Moreover, our findings support the idea
that the administration of IL-10 may be helpful in preventing
TLE development. Therefore, modulation of the IL-10/miR-187
axis may be a novel therapeutic target for TLE.
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